Curriculum Vitae
Prof. Dr Iris Löw-Friedrich
Name: | Prof. Dr med. Iris Löw-Friedrich |
Year of birth: | 1960 |
Nationality: | German |
First appointment: | 2014 (Amendment due to editorial error) |
Current appointment until: 2024
Current occupation:
- Chief Medical Officer UCB S.A., Brussels/Belgium (retiring from UCB in the course of 2024)
- Clinical professor for internal medicine, University of Frankfurt am Main Medical School, Frankfurt am Main/Germany (visiting, since 2000)
Professional career:
2008 - 2024 | UCB S.A. |
Chief Medical Officer and Vice President Development | |
2001 - 2009 | Pharma AG |
Global Head of Research and Development; since 2008 with UCB, | |
following the acquisition of Schwarz Pharma AG | |
2000 - 2001 | BASF Pharma |
Vice President Global Projects | |
Since 2000 | University of Frankfurt/Main |
Clinical professor for internal medicine | |
(visiting) | |
1992 - 2000 | Hoechst AG |
Various positions in Clinical Development, most recent position of Vice | |
President Clinical Development |
25
Qualifications: | |
1995 | Master Degree in Business Administration (Diplom- |
Kaufmann), University of Münster/DE |
Special qualifications as part of the skills profile or skills matrix:
- Capital Markets
- Accounting / P&L / Risk Management
- Auditing & Sustainability Reporting
- Controlling
- Digitization
- IT and Cybersecurity
- General Management
- Legal & Compliance
- Environment, Sustainability & Governance
- Procurement
- Investor & Corporate Communications
- Shared Services, Process & Commercial Excellence
- Social and HR
- Governance
Current group mandates: | |
• BIO Deutschland e.V., Berlin/DE | Member of the Board |
(not listed) |
Other current mandates:
- n/a
Latest update: April 2024
26
Curriculum vitae
Camilla Macapili Languille
Name: |  | Camilla Macapili Languille |
Year of birth: | 1983 | |
Nationality: | Canadian | |
First appointment: | 2022 |
Current appointment until: 2024
Current occupation:
- Head of Life Sciences, Mubadala Investment Company (MIC), Abu Dhabi, UAE
Professional career: | |
Since 2013 | Mubadala Investment Company (MIC), Abu Dhabi, UAE: |
Since 2018 | Director, Head of Life Sciences and DI Investment Committee |
member | |
2016 - 2018 | Senior Vice President, Technology |
2013 - 2015 | Utilities & Mining - Vice President, Head of Power |
2011 - 2013 | DAIWA CAPITAL (DC) ADVISORY PARTNERS, Paris, France |
Mergers & Acquisitions - Senior Manager | |
2007 - 2010 | VIRGIN MANAGEMENT LTD. (VIRGIN GROUP), London, UK |
Corporate Finance & Special Situations Portfolio - Investment | |
Manager | |
2005 - 2007 | JPMORGAN SECURITIES, INC., London, UK & New York, USA |
Mergers & Acquisitions, Consumer Healthcare & Retail - Analyst | |
Qualifications | |
2011 | Cours de Civilisation Française, Université Paris Sorbonne-IV |
2004 | Bachelor of Arts, Economics and Political Science, Columbia University, |
New York, USA |
27
Special qualifications as part of the skills profile or skills matrix:
- Biologics Manufacturing
- Biopharma
- Small Biotech
- Healthcare economics
- Capital Markets
- Accounting / P&L / Risk Management
- General Management
- Environment and Sustainability
- Governance
Current group mandates: | ||
• PCI Pharma Services (KPCI Holdings Limited), | Member of the Board of Directors | |
Philadelphia/USA | ||
(not listed) | ||
• Norstella (Caerus PikCo S.A.R.L.), New York/USA | Member of the Board of Directors | |
(not listed) | ||
• | Envirotainer A/S, Stockholm/SE | Member of the Board of Directors |
(not listed) | ||
• | va-Q-tec AG, Würzburg/DE | Member of the Board of Directors |
(listed on the Frankfurt Stock Exchange | ||
until 30 August 2023) |
Other current mandates:
- n/a
Latest update: April 2024
28
Curriculum Vitae
Dr Constanze Ulmer-Eilfort
Name: | Dr Constanze Ulmer-Eilfort |
Year of birth: | 1962 |
Nationality: | German |
First appointment: | 2021 |
Current appointment until: 2024
Current occupation:
- Partner of the law firm Peters, Schönberger & Partner, Munich/Germany
Professional career: | |
Since 2022 | Partner at the law firm Peters, Schönberger & Partner (PSP Munich) |
Until 2021 | Equity Partner at Baker McKenzie |
2012 - 2017 | Managing Partner in the German and Austrian offices of |
Baker McKenzie | |
2017 - 2021 | Member of the Global Executive Committee of Baker McKenzie |
Since 1994 | Baker McKenzie |
Qualifications: | |
1993 | 2nd State Legal Examination, Ludwig-Maximilians-Universität, Munich |
1993 | Doctorate (Dr. iur.) |
1989 | LL.M., University of Pennsylvania Carey Law School |
1987 | 1st State Legal Examination, Ludwig-Maximilians-Universität, Munich |
29
Special qualifications as part of the skills profile or skills matrix:
- M&A / Partnering
- General Management
- Legal & Compliance
- Environment and Sustainability, Sustainability Reporting
- Social and HR
- Governance
Current group mandates: | ||
• | Affimed NV, Mannheim/DE | Member of the Supervisory Board |
(listed on the NASDAQ) | ||
• | Proxygen GmbH, Vienna/AT | Member of the Advisory Board |
(not listed) |
Other current mandates:
- n/a
Latest update: April 2024
30
Curriculum Vitae
Dr Duncan McHale
Name: | Dr Duncan Philip McHale |
Year of birth: | 1966 |
Nationality: | British |
First appointment: | 2024 |
Current appointment until: -
Current occupation:
- Founder and Company Director of Weatherden Ltd, London, UK
Professional career: | |
Since 2017 | Weatherden Ltd |
Founder and Company Director | |
2017 - 2023 | Evelo |
Biosciences | Chief Medical Officer |
2011 - 2017 | UCB |
Vice President and Head Global Exploratory Development | |
208 - 2011 | AstraZeneca |
Various positions, most recent position of Vice President | |
Personalized Healthcare and Biomarkers | |
1999 - 2007 | Pfizer |
Various positions, most recent position of Executive Director, | |
European Head of Molecular Profiling and TA lead for Pain, Sex Health |
and Urology, Sandwich Laboratories, Pfizer Global Research and Development
31
Qualifications: | |
1996 - 1999 | Doctor of Philosophy - PhD, Human/Medical Genetics, |
University of Leeds, Leeds, UK | |
1985 - 1991 | Bachelor of Medicine, Bachelor of Surgery, University of |
Newcastle-Upon-Tyne,Newcastle-Upon-Tyne, UK |
Special qualifications as part of the skills profile or skills matrix:
- Research & development
- General Management
- M&A / Partnering
- Environment & Sustainability
- Governance
Current group mandates:
- n/a
Other current mandates:
- n/a
Latest update: April 2024
32
Curriculum Vitae
Wesley Wheeler
Name: | Wesley Wheeler |
Year of birth: | 1956 |
Nationality: | American |
First appointment: | 2024 |
Current appointment until: -
Current occupation:
- Operating Advisor to KKR, Madison Dearborn Partners and Edgewater Capital
- President, Wheeler Yacht Company, LLC, Chapel Hill, North Carolina, USA
- Managing Member, WPWheelerLLC
Professional career: | |
2019 - 2023 | UPS Healthcare |
President | |
2011 - 2019 | Marken |
Chief Executive Officer & Director | |
2007 - 2010 | Patheon (now a ThermoFisher company) |
President, Chief Executive Officer & Director | |
2003 - 2007 | Valeant Pharmaceuticals International (now Bausch Health) |
President | |
2002 - 2003 | DSM Pharmaceuticals |
Chief Executive Officer | |
1989 - 2002 | GlaxoSmithKline |
Different positions, last Senior Vice President, Manufacturing & Supply | |
1978 - 1989 | Exxon Research & Engineering (now ExxonMobil) |
33
Qualifications:
Master of Businss Administration, California
Lutheran University, Thousand Oaks, CA/USA
Bachelor of Sciences, Mechanical Engineering, Worcester Polytechnic
Institute, Worcester, MA/USA
Special qualifications as part of the skills profile or skills matrix:
- Research & Development
- Biologics Manufacturing
- Biopharma
- Small Biotech
- Commercial / B2B
- M&A / Partnering
- Capital Markets
- General Management
- Governance
Current group mandates: | ||
• | BioTouch International | Executive Chair of the Board |
• | Envirotainer A/S, SE | Member of the Board of |
Directors | ||
• | Belhaven Biopharma | Member of the Board of |
Directors | ||
• | Cairn Therrapeutics | Member of the Board of |
Directors |
Other current mandates:
- n/a
Last updated: April 2024
34
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Evotec SE published this content on 24 June 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 24 June 2024 17:28:49 UTC.